Will shares of Vertex Pharmaceuticals Incorporated (VRTX) do better than the market?
Wall Street is positive on Vertex Pharmaceuticals Incorporated (VRTX). On average, analysts give Vertex Pharmaceuticals Incorporated a Strong Buy rating. The average price target is $267.722, which means analysts expect the stock to fall -2.63% over the next twelve months. This average ranking earns Vertex Pharmaceuticals Incorporated an analyst rating of 40, which is better than 40% of the stock based on data compiled by InvestorsObserver.
Why are analyst ratings important?
A company’s financial statements are an important factor weighted by experts when analyzing a company’s health. Beyond the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shut down supply chains, causing consumption to change at worldwide. This knowledge allows investors to react to potential market changes before they are revealed in a quarterly announcement.
InvestorsObserver averages the ratings of all these analysts and ranks these averages into percentiles. This allows you to compare stocks in more detail than the usual five-level system used by the majority of investors.
What’s going on with Vertex Pharmaceuticals Incorporated stock today?
Vertex Pharmaceuticals Incorporated (VRTX) stock is up 0.95% while the S&P 500 is down -0.46% at 12:25 p.m. Thursday, April 7. VRTX gained $2.57 from the previous closing price of $272.39 on volume of 529,932 shares. Over the past year, the S&P 500 has risen 9.33% while VRTX has gained 29.26%. VRTX has earned $9.01 per share over the past 12 months, giving it a price-earnings ratio of 30.58. Click here for the full Vertex Pharmaceuticals Incorporated stock report.
Stay in the know
Subscribe to our daily morning update newsletter and never miss market news, moves and more.